Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

The earnings call indicates several concerns: a 12% revenue decrease, a significant cash position decline, and a going concern disclosure. Although cost-cutting measures are in place, the company is discontinuing therapeutic programs and reducing its workforce by 40%, which suggests financial strain. The Q&A section reveals a focus on restructuring and compliance, but lacks specific recovery timelines. The absence of a shareholder return plan and competitive pressures further contribute to a negative outlook, likely resulting in a stock price decrease of -2% to -8% over the next two weeks.
The earnings call reveals a widening EBITDA deficit and a significant decrease in cash reserves, indicating financial strain. Despite some positive developments like the GSK partnership and promising trial results, the lack of transparency around costs and the cybersecurity incident may cause investor concern. The focus on subscription models and market expansion is positive, but the financial health and guidance uncertainty suggest a negative stock reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.